

Corey M. Casey, Pharm.D.

SHAREHOLDER

Kansas City, MO | 816.572.4439
ccasey@polsinelli.com



Corey Casey is a registered patent attorney who brings his clinical and technical experience as a Doctor of Pharmacy and Registered Pharmacist to provide a real-world perspective in his practice as a patent attorney and litigator. Corey primarily practices in the areas of Hatch-Waxman and biologics patent litigation, including experience with *inter partes review* proceedings before the PTAB; patent preparation and prosecution; and IP estate assessment and due diligence.

Corey's practice is primarily focused on Hatch-Waxman patent infringement cases, representing both brand and generic companies. He has experience working on all aspects of cases, including pre-litigation strategy and opinions, fact and expert discovery, motion practice, trial and appeals. Corey also has experience and has served as counsel on multiple IPR matters at the PTAB, all in the pharmaceutical and medical device spaces. Beyond small-molecule pharmaceuticals, Corey has significant experience with due diligence and assessments of biosimilar products, drawing on his unique combination of technical and legal proficiency.

Corey also assists clients in managing the procurement and enforcement of domestic and international patent and trademark portfolios. He has extensive experience preparing freedom to operate, non-infringement and invalidity opinions for patent matters. He works with clients providing guidance and assistance in navigating the FDA regulatory process for new drug products, both prior to and after approval of the product. In addition, Corey serves as IP due diligence counsel in various M&A and investment transactions, taking a unique approach focused on an objective assessment of the portfolio, and the development of solutions to address any IP issues post-closing.

Representative pharmaceutical experience includes work with:

- Small molecules
- Novel compositions and formulations
- Drug delivery technologies
- Biologics and biosimilars

Capabilities

- Biosimilars
- Biotechnology & Life Sciences Patent Prosecution
- Hatch-Waxman & Biologics
- Intellectual Property
- Intellectual Property Counseling & Opinions
- Intellectual Property Litigation
- Life Sciences
- Patent Preparation & Prosecution
- Post-Grant Proceedings
- Technology
- Chemical Intellectual Property

Representative biotechnology experience includes work with:

- Antibodies
- Stem cell media
- Biomarker and analyte assay systems
- Cell lines and processes for developing biological products

Representative chemical experience includes work with:

- Pesticide formulations
- Hydrogel and related aqueous carrier technology
- Compositions and processes related to lithium battery products
- Ion-sequestering and oxidation-inhibiting compositions
- Reactors and processes for multi-stage oxidation

Education

- University of Missouri-Kansas City School of Law (J.D., 2009)
- University of Missouri-Kansas City (Pharm.D., 2006)

Bar Admissions

- Missouri, 2009
- Kansas, 2010
- Admitted to practice before the United States Patent and Trademark Office

Memberships

- American Intellectual Property Law Association
- Missouri Bar Association
- Kansas City Metropolitan Bar Association

Recognition

- Named a BTI Client Service All-Star, 2025
- Named one of *Best Lawyers: Ones to Watch® in America* in Litigation - Patent, 2025
- Selected for inclusion in the IAM Patent 1000 list of the World's Leading Patent Practitioners, 2022-2025, Missouri - Recommended
- Selected for inclusion in the *Missouri Lawyers Weekly* Up & Coming Awards, 2019

Publications

April 29, 2026

How Skinny is Skinny Enough? Takeaways from the SCOTUS Oral Argument in the Amarin/Hikma Case

January 20, 2026

Supreme Court Grants Cert. Petition in Hikma / Amarin Skinny Labeling Case

January 8, 2026

Polsinelli Life Sciences Spotlight - Volume 3 - Turning Insight into Action: A Life

Sciences Playbook for 2026

March 11, 2025

Federal Circuit Affirms District Court's Obviousness Judgment on ImmunoGen Patent Application

May 2024

Patent Basics for Biotech Counsel

Co-Contributor, Bloomberg Law